Plain language summary of publication: Comparing nivolumab and neoadjuvant chemotherapy with placebo and neoadjuvant chemotherapy in participants with newly diagnosed estrogen receptor-positive breast cancer in the CheckMate 7FL clinical trial

Le résumé fourni par la source

Plain Language SummaryWhat is this summary about?What is this summary about?This is a summary of a research article published in the scientific journal Nature Medicine. The article is on the CheckMate 7FL study that compared nivolumab + neoadjuvant chemotherapy with placebo + neoadjuvant chemotherapy in patients with newly diagnosed, high-risk ER+/HER2−breast cancer.In this study, 521 participants who had a complete clearance, also known as a pCR, of their cancer after treatment with nivolumab (an anti-cancer medication) and neoadjuvant chemotherapy were compared with those who received a placebo and neoadjuvant chemotherapy. The researchers also assessed the side effects of treatment with nivolumab or placebo in combination with neoadjuvant chemotherapy.They tried to identify specific groups of participants most likely to respond to and benefit from nivolumab and neoadjuvant chemotherapy by using a set of biological markers, also known as biomarker assessments.What were the results?The results from the study suggest that adding nivolumab to neoadjuvant chemotherapy can significantly increase pCR rates in patients with high-risk ER+/HER2− breast cancer.What do the results mean?Biomarkers are measurable indicators, such as specific cells, proteins, or other markers, that can provide information on how the body responds to treatment. New biomarkers can help identify the most suitable treatment for patients who are more likely to benefit from it.This is an abstract of the Plain Language Summary of Publication article.View the full Plain Language Summary PDF of this article to read the full-text

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.